Dynavax Technologies: Time To Refocus On Former Cash Cow CpG1018
Dynavax should take a leaf from its vaccine maker peer, Novavax, and work to monetize its CpG1018 adjuvant. Learn more about ...
News Medical39m
New nasal vaccine for COVID-19 set to begin clinical trial in the U.S.
A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug ...
MHRA grants Valneva marketing authorization for chikungunya vaccine
Valneva (VALN) announced that the Medicines and Healthcare products Regulatory Agency or MHRA has granted marketing authorization in the United ...
Valneva Receives Marketing Authorization in the UK for the World’s First Chikungunya Vaccine, IXCHIQ®
The UK approval marks the fourth regulatory approval Valneva has received for its single-shot chikungunya vaccine. The vaccine is currently approved in the United States (U.S.) 2, Europe 3 and Canada ...
Novavax Inc. stock outperforms competitors on strong trading day
Shares of Novavax Inc. NVAX rose 1.96% to $8.60 Wednesday, on what proved to be an all-around positive trading session for ...